BrainStorm Cell Therapeutics (BCLI) Flash Note 30092024

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s). BCLI on Friday confirmed its reverse stock split (R/S) to become effective today 30 Sept 2024 (to maintain Nasdaq listing). Reverse stock splits are often (though not always) an effective mechanism and often lead to an upwards re-rating as psychological market factors come into play. There is also a usual market clearing mechanism that often leads to net selling in the early days. BCLI has also announced 24 Sept, the acceptance of two extracts featuring NurOwn® and subject to a successful reverse split we would expect a number of positive new announcements with respect to the PIIIb trial rollout.